Key Drivers
- Strong liquidity
- Negative returns
- Recent profitability
AIAI Summary
Natera has shifted from a binary, evidence‑burn model to a commercial inflection driven by Signatera adoption, Zenith WGS and high gross margins plus ~$1.08B cash, creating a credible near‑term path to profitable scale if mid‑20%+ revenue growth and strict OpEx discipline hold. Key actionable risk: be outcome‑contingent—maintain exposure only while revenue/FCF trends and reimbursement wins persist, and cut or downgrade quickly on payer setbacks, pivotal readout delays, or OpEx creep that invalidate the premium multiple.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Negative returns
- •Recent profitability
NTRA: Strong balance sheet and cash generation contrast with full‑year operating losses and deeply negative returns, though recent quarterly profitability hints at recovery while the market prices in substantial improvement.
Price Behavior
Key Price Behavior Insights:
- •Below short-term MA
- •Nearby support band
- •Lower highs sequence
Over the last month the stock has slid from the low‑$210s to $195.28, trading below its ~$202.10 last‑month moving average with weakening momentum and lower highs implying continued short‑term selling risk while buyers have held the $187–$200 band and resistance sits at $210–$216 (with stronger supply near $235–$242).
Sharp drop on 2026-03-20 from $202.73 to accelerate selling
Sentiment & News
Key News Insights:
- •Revenue acceleration
- •Product expansion
- •Clinical validation
Natera reported accelerating revenue and product expansion—beat Q4 results, launched a whole‑genome assay, gained clinical validation for Signatera, and saw mixed institutional trading.
Strong commercial momentum, broadened diagnostic offerings, and peer‑reviewed evidence should bolster investor confidence and support share‑price upside if growth persists
Similar Companies in Healthcare
Other companies in the same sector with AI ratings